grant
Role of carnosine in peripheral arterial disease
Organization UNIVERSITY OF LOUISVILLELocation LOUISVILLE, UNITED STATESPosted 15 Aug 2024Deadline 31 May 2029
NIHUS FederalResearch GrantFY20253-Aminopropionic AcidASCVDATP SynthesisATP Synthesis PathwayAbscissionActive Follow-upAerobicAffectAfter CareAfter-TreatmentAftercareAldehydesAmericanAnkleArterial Fatty StreakArterial Obstructive DiseasesArterial Obstructive DisorderArterial Occlusive DiseasesArterial Occlusive DisorderArteriesAtheromaAtheromatousAtheromatous degenerationAtheromatous plaqueAtherosclerosisAtherosclerotic Cardiovascular DiseaseAttenuatedBindingBiopsyBlood flowBody TissuesBuffersCardiacCarnosineCell TherapyCharcot's syndromeChronicClinical ManagementClinical TrialsD-GlucoseDataDefectDextroseDipeptidesDouble-Blind MethodDouble-Blind StudyDouble-BlindedDouble-Masked MethodDouble-Masked StudyDrug TherapyDysfunctionEffectivenessEnrollmentEnzyme GeneEnzymesExcisionExcretory functionExerciseExtirpationExtremitiesFDA approvedFemaleFibrosisFood SupplementsFoundationsFunctional disorderGeneralized GrowthGlucoseGoalsGrowthHindlimbHistidineImpairmentIntermediary MetabolismIntermittent ClaudicationInterventionIschemiaIschemia-Reperfusion InjuryIsolated limb perfusionLaboratoriesLegLimb PerfusionLimb structureLimbsLipid PeroxidationLower ExtremityLower LimbMR ImagingMR SpectroscopyMR TomographyMRIMRIsMagnetic Resonance ImagingMagnetic Resonance SpectroscopyMeasuresMediatingMedicalMedical Imaging, Magnetic Resonance / Nuclear Magnetic ResonanceMembrum inferiusMetabolicMetabolic ProcessesMetabolic dysfunctionMetabolismMetalsMiceMice MammalsMitochondriaMolecular InteractionMorbidityMorbidity - disease rateMurineMusMuscleMuscle TissueMuscle functionNMR ImagingNMR TomographyNon-TrunkNuclear Magnetic Resonance ImagingObstructionOperative ProceduresOperative Surgical ProceduresOutcome StudyParticipantPathological ConstrictionPathway interactionsPatientsPerformancePerfusionPeripheral arterial diseasePersonsPharmacological TreatmentPharmacotherapyPhase 3 Clinical TrialsPhase III Clinical TrialsPhysiopathologyPlacebosPreclinical dataProcessPropertyProteomicsQOLQuality of lifeRandomizedRegio tarsalisRemovalReperfusion DamageReperfusion InjuryRestRisk FactorsRoleSecondary toSham TreatmentSkeletal MuscleStenosisStentsSupplementationSurgicalSurgical InterventionsSurgical ProcedureSurgical RemovalTestingTherapeuticTherapeutic InterventionTimeTissue GrowthTissuesTransition ElementsVoluntary MuscleWalkingZeugmatographyactive followupangiogenesisatheromatosisatherosclerosis plaqueatherosclerotic diseaseatherosclerotic lesionsatherosclerotic plaqueatherosclerotic vascular diseaseattenuateattenuatesblood perfusioncardiovascular disease riskcardiovascular disorder riskcell based interventioncell mediated interventioncell mediated therapiescell-based therapeuticcell-based therapycellular therapeuticcellular therapychelationclaudicationclinical efficacycostdesigndesigningdrug interventiondrug treatmentefficacy testingenrollexcretionexercise capacityfeedingfollow upfollow-upfollowed upfollowuphemodynamicsimprovedindexingintervention therapylimb losslost limbmalemetabolism measurementmetabolomicsmetabonomicsmitochondrialmortalitymuscle physiologymuscularnovelontogenypathophysiologypathwayperformance in walkingperipheral artery diseasepharmaceutical interventionpharmacological interventionpharmacological therapypharmacology interventionpharmacology treatmentpharmacotherapeuticsphase III protocolplaques in atherosclerosispost treatmentpre-clinicalpreclinicalpreclinical findingspreclinical informationpreventpreventingprimary outcomeprotein expressionrandomisationrandomizationrandomly assignedresectionrevascularization surgerysecondary outcomesham therapyskeletal muscle metabolismskeletal muscle protein metabolismsocial rolestandard of caresuccesssurgerytransition metaltreadmillurinarywalking performanceβ-Alanine♀♂
Description preview
Abstract
Peripheral arterial disease is a serious manifestation of atherosclerosis in the lower
extremities. Current interventions approved by FDA are either ineffective or have a
modest effect. Surgical revascularization is the only viable option for PAD subjects;
however, the stents can fail. Patients with PAD have marked defects in skeletal…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click